Defining clinical remission and clinically inactive disease in juvenile systemic lupus erythematosus (jSLE) by Mina, Rina et al.
ORAL PRESENTATION Open Access
Defining clinical remission and clinically inactive
disease in juvenile systemic lupus erythematosus
(jSLE)
Rina Mina
1*, Laura Schanberg
2, Anne B Eberhard
3, Marisa Klein–Gitelman
4, Gloria Higgins
5, Karen Onel
6,
Nora G Singer
7, Kathleen O’ Neil
8, Lori Tucker
9, Deborah Levy
10, Wajeeha Yousaf
11, Shannen Nelson
1,
Michael Beresford
12, Ruben Cuttica
13, Graciela Espada
14, Angelo Ravelli
15, Alberto Martini
15, Edward Giannini
1,
Hermine I Brunner
1
From 18th Pediatric Rheumatology European Society (PReS) Congress
Bruges, Belgium. 14-18 September 2011
Background
An initial Delphi survey delineated key commonalities
for a standard definition of clinical remission and inac-
tive disease in jSLE. However, several additional clarifi-
cations were still required.
Objective
To develop a definition and criteria of clinical remission
and inactive disease in jSLE.
Methods
A second international Delphi survey was conducted
among pediatric rheumatologists. Consensus was set at
75%.
Results
There were 210 respondents. Consensus was achieved
regarding the key definitions under consideration (Table
1). Respondents also agreed that a) there should be at
most one mild, non-limiting symptom; and b) there can
be regular use of several systemic medications in clinical
remission. There was no consensus on whether select
laboratory tests could be abnormal, and whether regular
use of non-steroidal anti-inflammatory drugs with clini-
cal remission was permissible.
Conclusions
Consensus has been reached on the definition of ‘Clini-
cal Remission’ and ‘Clinically Inactive Disease’ in jSLE.
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Table 1 Definition of Clinical Remission and Clinically Inactive Disease in JSLE
Construct Time frame Acceptable Use of Medications for Lupus Consensus
Cortico
steroids
Immuno
suppressives
Preventive
medications
Medications to treat
SLE damage
Clinically Inactive Disease Time-point Yes Yes Yes Yes 94% (156/
166)
Clinical Remission on
Medication
Time-period: ≥ 6
months
Yes Yes Yes Yes 96% (159/
166)
Clinical Remission on
Preventive Medication
Time-period: ≥ 6
montHs
No No Yes Yes 95% (154/
162)
Clinical Remission Off
Medication
Time-period: ≥ 12
months
No No No Yes 86% (140/
162)
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